Pirtobrutinib (Jaypirca®), a first-in-class noncovalent Bruton tyrosine kinase (BTK) inhibitor, has been approved by the FDA for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) ...
The goal of CLL management is to maintain the best quality of life and treat only when patients become symptomatic from their disease. 7,8 Unlike other hematologic malignancies, CLL is a long-term, ...
In a recently published study, researchers at Fox Chase Cancer Center revealed for the first time that cancer cells can evade anti-cancer drugs by entering and surviving within bone marrow fibroblasts ...
Efficacy of first-line treatment for chronic lymphocytic leukemia: A Bayesian network meta-analysis.
Incidence, predictors and outcomes of cardiovascular events in patients with chronic lymphocytic leukemia. Summary of NMA results: PFS of zanubrutinib compared with frontline treatments for TN CLL.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback